FindTrial
Sign In

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT01613053
Acronym
MACS2226
Enrollment
Unknown
Registered
2012-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2015-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Stromal Tumor

Keywords

Gastrointestinal Stromal Tumor, GIST

Brief summary

Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.

Detailed description

Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial, all five patients will receive Glivec (8oomg per day) treatment until tumor progression \[by RECIST guidelines, version 1.0\], unacceptable toxicity, death or withdrawal of consent.

Interventions

DRUGGlivec

800 mg per day

Sponsors

Novartis Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained.

Exclusion criteria

* N/A.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026